Medacta International Introduces New Approach to Posterior Lumbar Midline Cortical Screw Placement with Customizable MySpine MC Surgical Guides

May 23, 2018

CASTEL SAN PIETRO, Switzerland–(BUSINESS WIRE)–Medacta International, the family-owned global leader in innovative joint replacement and spinal technologies, announced clearance from the U.S. Food and Drug Administration (FDA) and the addition of MySpine Midline Cortical Pedicle Screw Placement Guide (MySpine MC) to its MySpine portfolio. The first two stateside surgeries utilizing MySpine MC were conducted this month, first by Nima Salari, M.D., of Scottsdale Shea Medical Center in Scottsdale, Arizona, followed by Jeffrey Henn, M.D., of Lee Memorial Hospital in Fort Myers, Florida.

MySpine MC enables surgeons to optimize procedures for both outpatient and inpatient settings and foster more rapid patient recovery through an accurate and reliable muscle-sparing approach to posterior lumbar surgery. This new technology guides the screw to a trajectory in the pedicle that evolved from the well-established cortical bone trajectory (CBT). Through accurate CT-based preoperative planning of a more caudomedial entry point than traditional pedicle screw trajectories and a less extreme caudal-cranial angle than CBT, the MySpine MC technique avoids interference with the cranial facet joints and accommodates larger screw diameters and lengths, with four points of cortical bone purchase for enhanced biomechanical fixation.

Achieving this improved screw trajectory through a small midline incision with a patient-matched guide can bring speed and reliability to the operating room, while potentially accelerating patient recovery and decreasing the risk of pedicle fractures, facet joint violation and nerve root injury. The intraoperative utilization of 3D-printed guides for pedicle screw placement facilitates accurate replication of pre-surgical planning to achieve the fine-tuned screw trajectory and may further reduce radiation exposure, muscular dissection and operative time.

Dr. Salari’s patient, the first to undergo surgery with MySpine MC, had dynamic spondylolisthesis at the L4/L5 level with severe spinal stenosis and neurogenic claudication, complicated by a history of diabetes and cardiovascular disease. “Given my patient’s condition and history,” Dr. Salari said, “I needed a minimally invasive option that would allow for a wide central decompression reinforced by excellent stabilization. We also needed to minimize anesthesia time for the patient, so it needed to be quick. The ability to pre-plan the surgery and work with a product that had been fully customized for the patient proved incredibly valuable. The surgery was fast, the screw placement was accurate, and the fixation was reliable. To top it off, we were able to reduce the need for intra-operative fluoroscopy, limiting the patient’s radiation exposure.”

Dr. Henn’s patient, who had severe stenosis and spondylolisthesis, is an athlete who was looking for the least invasive surgical solution. His goal was a relatively rapid return to his training and racing. Regarding the surgery, Dr. Henn said: “My patient’s pathology required decompression and instrumented fusion, historically a significant surgery with a long recovery. Using Medacta’s MySpine technology, prior to the procedure I was able to perform detailed surgical planning based on his specific anatomy. The result was a highly successful surgery, which I was able to perform in minimal time through a small incision. The MySpine guides worked flawlessly and, as a result, the need for intraoperative radiation was minimized, which was better for the patient and for the surgical team. The patient did very well and within one day of surgery, was walking extensively and reported less pain than he had prior to surgery – clearly a benefit of using the MySpine MC minimally invasive technique. I was extremely pleased with the system, and my patient was even more so.”

First introduced in 2014, Medacta’s MySpine technology can be customized for each patient’s anatomy and surgeon’s preferences and has been associated with greater accuracy of pedicle screw positioning, compared to freehand and other techniques, as well as reduced radiation, operative time and hospital stay. MySpine MC expands upon those benefits by enabling a biomechanically superior screw trajectory achieved through a minimally invasive approach. Surgeons across Europe, Australia and Asia have utilized MySpine MC and this novel multi-cortical approach in more than 100 spinal surgeries to date. MySpine MC is also supported by the Medacta Orthopaedic Research and Education (M.O.R.E.) Institute, providing continuous educational and developmental support to Medacta surgeons as they work towards discovering new technologies and supporting patients.

“Medacta is known for disrupting surgical techniques with technology-backed approaches that are both surgeon- and patient-friendly,” said Francesco Siccardi, Executive Vice President of Medacta International. “Minimally invasive cortical bone fixation makes sense for posterior lumbar surgeries, but the technology to optimize and support it was lacking for many years. MySpine MC provides the answer to that need for the benefit of patients and surgeons alike.”

For more information on MySpine MC, visit Medacta’s MySpine webpage.

About Medacta International

Medacta® International is a world leading manufacturer of orthopedic implants, neurosurgical systems, and instrumentation. Medacta’s revolutionary approach and responsible innovation have resulted in standard of care breakthroughs in spine, as well as hip and total knee replacement. Over the last 19 years, Medacta has grown dramatically by taking a different approach and placing value on all aspects of the care experience from design to training to sustainability. Medacta is headquartered in Castel San Pietro, Switzerland, and operates in over 30 countries. To learn more about Medacta International, please visit www.medacta.com or follow @Medacta on Twitter.

Contacts

For Medacta International
Jill Bongiorni, 516-729-2250
Jill@torchcomllc.com

Zimmer Biomet Announces 510(k) Clearance for Zyston® Strut Open Titanium Interbody Spacer System

WARSAW, Ind.May 22, 2018 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Zyston® Strut Open Titanium Interbody Spacer System. This marks Zimmer Biomet’s first titanium spinal implant manufactured via a 3D printing process.

The Zyston Strut Open Titanium System is a family of lumbar cages designed to enhance the strength, graft capacity and visualization of the interbody spacer in spinal fusion cases. The cages will be available in a series of sizes to accommodate a range of patient anatomies and surgical approaches. The System also includes surgical instruments for insertion, manipulation and removal of the implants.

“The Zyston Strut Open Titanium Interbody Spacer System is available in straight and curved profiles and is uniquely designed to provide surgeons with an option that optimizes the balance of strength and graft capacity in spinal fusion cases,” said board certified orthopaedic surgeon Frank Schwab, MD, New York, NY. “I have worked with a variety of Zimmer Biomet’s spine products and am looking forward to offering my fusion patients this latest innovation.”

“The Zyston Strut Open Titanium Spacer is manufactured using a 3D printing process, which allows us to create a unique cage architecture that maximizes graft volume prior to implantation,” said Rebecca Whitney, General Manager of Zimmer Biomet’s Spine division. “The System marks our first 3D printed titanium spinal implant and adds to our comprehensive offering of lumbar spacers that are available in PEEK®-Optima, Trabecular Metal™ Technology and allograft.”

About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Cautionary Statement Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes. Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially. For a list and description of some of such risks and uncertainties, see Zimmer Biomet’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC). These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC. Forward-looking statements speak only as of the date made. Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Readers of this release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate. This cautionary statement is applicable to all forward-looking statements contained in this release.

ZBH-Corp

SOURCE Zimmer Biomet Holdings, Inc.

Related Links

http://www.zimmerbiomet.com

Mainstay Medical Announces CFO Transition

May 22, 2018

DUBLIN–(BUSINESS WIRE)–

Mainstay Medical International plc (“Mainstay” or the “Company”, Euronext Paris: MSTY.PA and Euronext Dublin: MSTY.IE), a medical device company focused on bringing to market ReActiv8®, an implantable restorative neurostimulation system to treat disabling Chronic Low Back Pain, announces that Mr. Hugh Kavanagh is to step down as Chief Financial Officer (“CFO”) and leave Mainstay with effect from 21 August 2018. The process to recruit a successor has commenced and a further announcement will be made in due course.

Mr. Kavanagh has been CFO of Mainstay since 2013. He was instrumental in leading the Company through its IPO on Euronext Paris and the ESM of the Irish Stock Exchange in 2014, and its subsequent debt and equity fundraisings. Hugh provided financial leadership for the Company through the development phase of ReActiv8 and to its commercialization in Europe.

Jason Hannon, CEO of Mainstay, said: “On behalf of Mainstay’s Board, management team and staff, I would like to thank Hugh for his substantial contribution to the growth of the Company. This is an exciting time for the Company as we look forward to results from our US IDE Study of ReActiv8 and as the Company increases its focus on preparing for commercialization in the US market. The Company plans to announce the appointment of a new CFO in the coming months. We are pleased that Hugh will continue to support the Company through this transition. We wish him all the best for the future.”

About Mainstay

Mainstay is a medical device company focused on bringing to market an innovative implantable restorative neurostimulation system, ReActiv8®, for people with disabling Chronic Low Back Pain (CLBP). The Company is headquartered in Dublin, Ireland. It has subsidiaries operating in Ireland, the United States, Australia, Germany and the Netherlands, and is listed on the regulated market of Euronext Paris (MSTY.PA) and the ESM of Euronext Dublin (MSTY.IE).

About Chronic Low Back Pain

One of the recognized root causes of CLBP is impaired control by the nervous system of the muscles that dynamically stabilize the spine in the low back, and an unstable spine can lead to back pain. ReActiv8 is designed to electrically stimulate the nerves responsible for contracting these muscles and thereby help to restore muscle control and improve dynamic spine stability, allowing the body to recover from CLBP.

People with CLBP usually have a greatly reduced quality of life and score significantly higher on scales for pain, disability, depression, anxiety and sleep disorders. Their pain and disability can persist despite the best available medical treatments, and only a small percentage of cases result from an identified pathological condition or anatomical defect that may be correctable with spine surgery. Their ability to work or be productive is seriously affected by the condition and the resulting days lost from work, disability benefits and health resource utilization put a significant burden on individuals, families, communities, industry and governments.

Further information can be found at www.mainstay-medical.com

CAUTION – in the United States, ReActiv8 is limited by federal law to investigational use only.

PR and IR Enquiries:
Consilium Strategic Communications (international strategic communications – business and trade media)
Chris Gardner, Jessica Hodgson, Nicholas Brown, +44 203 709 5700 / +44 7921 697 654
mainstaymedical@consilium-comms.com
or
FTI Consulting (for Ireland):
Jonathan Neilan, +353 1 765 0886
jonathan.neilan@fticonsulting.com
or
NewCap (for France)
Julie Coulot, +33 1 44 71 20 40
jcoulot@newcap.fr
or
Investor Relations:
LifeSci Advisors, LLC
Brian Ritchie, + 1 (212) 915-2578
britchie@lifesciadvisors.com
or
ESM Advisers:
Davy
Fergal Meegan or Barry Murphy, +353 1 679 6363
fergal.meegan@davy.ie or barry.murphy2@davy.ie

Forward looking statements

This announcement includes statements that are, or may be deemed to be, forward looking statements. These forward looking statements can be identified by the use of forward looking terminology, including the terms “anticipates”, “believes”, “estimates”, “expects”, “intends”, “may”, “plans”, “projects”, “should”, “will”, or “explore” or, in each case, their negative or other variations or comparable terminology, or by discussions of strategy, plans, objectives, goals, future events or intentions. These forward looking statements include all matters that are not historical facts. They appear throughout this announcement and include, but are not limited to, statements regarding the Company’s intentions, beliefs or current expectations concerning, among other things, the Company’s results of operations, financial position, prospects, financing strategies, expectations for product design and development, regulatory applications and approvals, reimbursement arrangements, costs of sales and market penetration.

By their nature, forward looking statements involve risk and uncertainty because they relate to future events and circumstances. Forward looking statements are not guarantees of future performance and the actual results of the Company’s operations, and the development of its main product, the markets and the industry in which the Company operates, may differ materially from those described in, or suggested by, the forward looking statements contained in this announcement. In addition, even if the Company’s results of operations, financial position and growth, and the development of its main product and the markets and the industry in which the Company operates, are consistent with the forward looking statements contained in this announcement, those results or developments may not be indicative of results or developments in subsequent periods. A number of factors could cause results and developments of the Company to differ materially from those expressed or implied by the forward looking statements including, without limitation, the successful launch and commercialization of ReActiv8, the progress and success of the ReActiv8-B Clinical Trial, general economic and business conditions, the global medical device market conditions, industry trends, competition, changes in law or regulation, changes in taxation regimes, the availability and cost of capital, the time required to commence and complete clinical trials, the time and process required to obtain regulatory approvals, currency fluctuations, changes in its business strategy, political and economic uncertainty. The forward-looking statements herein speak only at the date of this announcement.

Short Name: Mainstay Medical
Category Code: STR
Sequence Number: 647953
Time of Receipt (offset from UTC): 20180521T205352+0100

Contacts

Mainstay Medical

Providence Medical Technology Announces FDA 510(k) Clearance for DTRAX® Spinal System

PLEASANTON, Calif.May 22, 2018 /PRNewswire/ — Providence Medical Technology, Inc., a manufacturer of innovative instruments and implants for cervical fusion surgery, today announced it has received 510(k) clearance from the United States Food and Drug Administration (FDA) for its DTRAX® Spinal System (“DTRAX”) to be specifically indicated for use in posterior cervical fusion in patients with cervical degenerative disc disease. This 510(k) clearance provides a more specific indication for the DTRAX Spinal System, which was a Class I medical device more broadly indicated for access and preparation of a spinal joint to aid in fusion.

“With the FDA 510(k) clearance of DTRAX Spinal System, Providence now has the only sterile-packaged, single-use set of instruments specifically cleared for posterior cervical fusion,” said Providence CEO Jeff Smith. “Our unique, single-use instruments assist surgeons in performing the steps of a traditional posterior cervical fusion. We believe DTRAX represents a landmark innovation for cervical fusion benefiting patients, surgeons, facilities, and payers.”

About DTRAX Spinal System
The DTRAX Spinal System is a set of surgical instruments indicated for performing posterior cervical fusion in patients with cervical degenerative disc disease. The system consists of several specialized single-use instruments including a facet joint access instrument, lateral mass decortication trephine, mallet, cannula, decortication rasp, decortication burr, and bone graft tamp.

These instruments allow surgeons to access the posterior cervical spine to perform posterior cervical fusion by decorticating the bony surfaces of the posterior lateral mass and articular surfaces of the facet joints. The instruments then enable the application of autograft or allograft bone. The diameter of the largest instrument is less than 1cm, which allows the surgeon to use a variety of surgical techniques including a tissue-sparing technique that reduces the dissection and stripping of muscles. View a video animation of the surgical technique

About Providence
Providence Medical Technology, Inc. is a privately-held medical device company focused on innovative solutions for cervical spinal conditions. The company has pioneered a proprietary approach to posterior cervical fusion and has developed surgical instrumentation and implants that offer unique benefits to the $2 billion worldwide cervical spine market.

The Providence family of products includes the DTRAX® Spinal Instrumentation System, CAVUX® intervertebral implants, and ALLY® bone and facet screws. All products are sterile-packaged and single-use to maximize perioperative efficiency and ensure consistent quality and performance.

For more information, please visit www.providencemt.com.

 

SOURCE Providence Medical Technology, Inc.

Related Links

http://www.providencemt.com

In’Tech Medical enters into agreement to acquire Bradshaw Medical, industry leader in silicone overmolded solutions, ratchet and torque devices

In’Tech Medical SAS (http://www.intech-medical.com), the leading Contract Manufacturer of medical devices in Orthopedics, announced today that it has entered into a binding agreement to acquire world renowned instruments and silicone overmold company, Bradshaw Medical Inc. The transaction, supported by Eurazeo PME, has been approved by the Board of Directors of both organizations.

Based in Kenosha, Wisconsin, Bradshaw Medical is an innovation-driven company that has built a first-class reputation with a relentless focus on customer service.

With over 40 issued patents, Bradshaw’s engineering team has designed a broad portfolio of OEM instruments and provides the industry with highly-customizable silicone overmolded solutions.

“With the addition of Bradshaw Medical to the In’Tech family, we are re-enforcing our position as a leading Contract Manufacturer of surgical instruments in Orthopedics, as well as adding significant market penetration power,” said Laurent Pruvost, President of the In’Tech Medical Group. “Enhancing our offering with Bradshaw’s high-quality OEM instruments portfolio and its silicone overmolding expertise, provides the group with unparalleled capabilities and scale. Together we look forward to reshaping the orthopedic market, with game changing “smart” instruments.”

With over 800 employees and projected 2018 revenues of approximately $120 million, In’Tech Medical is now a premiere engineering powerhouse, capable of delivering manufacturing solutions anywhere, at any time, to the benefit of medical device organizations worldwide.

“Bradshaw Medical is excited to begin this next chapter in our company’s history,” said Guy Bradshaw, Founder & CEO. “We take great pride in providing the industry with the highest quality surgical instrumentation and customer service. Our tremendous growth and success over the past 12 years is a direct reflection of our dedicated employees. Forming an alliance with In’Tech Medical will allow us to take our brand global and provide the orthopedic industry with our combined ground-breaking technology.”

In’Tech and Bradshaw will be exhibiting jointly at OMTEC, in Chicago, June 12-14 and look forward to sharing with everyone the group’s vision of the instruments for tomorrow.

About In’Tech Medical (OMTEC booth #630)
Founded in France in 2000, In’Tech Medical is a global leading contract-manufacturer of surgical instruments, implants, as well as sterilization cases and trays. Powered by 650 dedicated employees across the USA, Europe and Asia-Pacific, the company is strategically positioned to deliver customized solutions to complex engineering and supply chain challenges. Driven by innovation, In’Tech continuously enhances its product & service offering to accelerate time-to-market for its customers worldwide.

Since July 2017, In’Tech Medical’s development strategy is supported by Eurazeo PME and Andera Partners (formerly Edmond de Rothschild Investment Partners) alongside its management team.

About Bradshaw Medical (OMTEC booth #226)
Founded in 2006, Bradshaw Medical Inc. is an industry leader in specialized design and development of OEM and spinal instrumentation. Bradshaw Medical has continually evolved over the past decade to meet the most demanding requirements of the orthopedic marketplace.

Fuse Medical, Inc. Files Quarterly Report on Form 10-Q

May 21, 2018

RICHARDSON, Texas–(BUSINESS WIRE)–Fuse Medical, Inc., (OTC: FZMD), (“Fuse” or the “Company”), announced that it has filed its quarterly report on Form 10-Q for the first quarter ended March 31, 2018, with the United States Securities and Exchange Commission, (the “SEC”) on Tuesday, May 15, 2018.

Christopher C. Reeg, Chief Executive Officer, commented, “We are pleased to report our first quarter of 2018 results with increases of approximately 7% and 14%, for net revenue and gross profit, respectively, compared to the same period one year ago. With the successful completion of our acquisition of CPM Medical Consultants, LLC, reflected positively in our 2017 Annual Report on Form 10-K filing, all of us at Fuse are very excited about what this partnership will mean for our next phase of growth, as well as the benefits it offers our customers. We are pleased with our progress and will continue to execute our strategic objectives.”

The filing can be found on the Company’s website at http://www.fusemedical.com/investors.

About Fuse Medical, Inc.

Fuse is a national distributor of medical devices, who provides a broad portfolio of internal and external fixation products; upper and lower extremity plating and total joint reconstruction; soft tissue fixation and augmentation for sports medicine procedures; full spinal implants for trauma, degenerative disc disease, and deformity indications, (collectively, “Orthopedic Implants”) and a wide array of osteo-biologics and regenerative tissue which include human allografts, substitute bone materials, tendons, and regenerative tissues and fluids (“Biologics”). The Company’s broad portfolio of Orthopedic Implants and Biologics provide high-quality products to assist surgeons with positive patient outcomes and cost-effective solutions for its customers. For more information about Fuse, please visit: www.fusemedical.com.

Forward-Looking Statements

Certain statements in this press release, including those related to an anticipated purchase of all of the outstanding membership units and plans for the consolidated company, constitute “forward-looking statements” within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend,” or similar expressions or statements regarding intent, belief, or current expectations, are forward-looking statements. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based only on information available to the Company as of the date of this release. These forward-looking statements are based upon current estimates and assumptions and are subject to various risks and uncertainties, including, without limitation, those set forth in the Company’s filings with the SEC; the failure of the Company to close the transaction; and integration issues with the consolidated company. Thus, actual results could be materially different. The Company expressly disclaims any obligation to update or alter statements whether as a result of new information, future events, or otherwise, except as required by law.

Contacts

Fuse Medical, Inc.
Devon Peddie, 469-862-3030
Investor Relations Analyst
Facsimile: 469-862-3035
info@Fusemedical.com

Exactech Provides Powerful Combination of Computer Technology and Award-Winning Instrumentation for Revision Knee Surgery

May 22, 2018

GAINESVILLE, Fla.–(BUSINESS WIRE)–Exactech, a developer and producer of bone and joint restoration products and biologic solutions for extremities, knee and hip, announced today that two of its leading technologies were used in combination for the first time to support a revision total knee surgery. Bernard Stulberg, MD, at the St. Vincent Charity Medical Center in Cleveland, Ohio, performed the first case using the new ExactechGPS® revision knee software application (RTKA), along with the company’s award-winning Truliant® Knee System instrumentation.

ExactechGPS is a surgeon-controlled, computer-assisted surgical technology that provides real-time, intraoperative data during total joint arthroplasty. The RTKA application helps orthopaedic surgeons address complex primary and challenging revision cases by providing insights into the diseased joint, feedback of anatomical and mechanical alignment, component sizing and resection validation.

According to Dr. Stulberg, a revision knee specialist, “I had the opportunity to experience firsthand the powerful potential of the Truliant instrumentation combined with ExactechGPS. The RTKA application revealed the existing abnormalities that caused my patient’s disability, and helped guide the sizing and positioning of the implants. The result was restoration of alignment and stability of a previously unstable total knee arthroplasty.”

ExactechGPS has a proven ability to achieve high accuracy and precision in resection alignment1 and is the only computer-assisted surgical technology to offer surgeons advanced ligament balancing options for RTKA. Fully integrated with the ExactechGPS technology, Exactech provides a comprehensive array of revision implant options, including metaphyseal cones, stems, augments and offset couplers.

“Exactech’s revision system leaves no doubt it can simplify procedures, while providing the framework to consistently deliver successful results for the wide range of complications in RTKA,” Stulberg said. “I am fully confident this will result in significant and meaningful benefits for both the surgeon and the patient.”

The Truliant Revision instrumentation has full U.S. market availability. The ExactechGPS RTKA application is currently in pilot launch with full availability expected in the second half of the year. For more information, visit www.TruliantKnee.com.

1. Dai Y et al. Total Knee Arthroplasty Using a Contemporary Computer Assisted Surgical System: A Review of Resection Alignment on 8,000 Clinical Cases. ORS Best Implant Poster Award. 2018.

About Exactech

Based in Gainesville, Fla., Exactech develops and markets orthopaedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians. The company manufactures many of its orthopaedic devices at its Gainesville facility. Exactech’s orthopaedic products are used in the restoration of bones and joints that have deteriorated as a result of injury or diseases such as arthritis. Exactech markets its products in the United States, in addition to more than 30 markets in Europe, Latin America, Asia and the Pacific. Additional information about Exactech can be found at http://www.exac.com.

Contacts

Exactech
Media Contact:
Priscilla Bennett, APR, 352-377-1140
VP of Corporate and Marketing Communications

Xtant Medical Receives FDA 510(K) Clearance for InTice(TM)-C Porous Titanium Cervical Interbody System

BELGRADE, MT / ACCESSWIRE / May 21, 2018 / Xtant Medical Holdings, Inc. (NYSE American: XTNT), a leader in the development of regenerative medicine products and medical devices, announces U.S. Food and Drug Administration (FDA) 510(k) clearance for InTice™-C Porous Titanium Cervical Interbody System.

InTice-C is designed using OsteoSync Ti, a best-in-class, cost-effective, highly porous titanium scaffold material for improved implant fixation. The material more closely resembles the bioscaffold of cancellous bone, and further combines Xtant Medical’s hardware and biologic portfolios. In addition to InTice-C serving as a bioactive scaffold, it is also cleared for use with Xtant’s proprietary allograft lines, including OsteoSponge®, 3Demin® Cortical Fibers, and OsteoVive™ viable cell allograft.

“InTice-C represents Xtant’s latest addition to our spinal implant portfolio and is our first spinal implant to be engineered using a best-in-class porous titanium material,” stated Dr. Gregory Juda, Chief Scientific Officer and General Manager of Xtant Medical. “The porous architecture of the titanium was designed to improve implant fixation, both prior and post fusion. We expect a positive reception of this technology from our surgeon customers in the cervical spine market.”

The InTice-C Is designed to provide cervical intervertebral body fusion options for each patient’s varied anatomy. It is offered in multiple footprint, height and endplate options. The commercial pure titanium structure offers continuous pore interconnectivity from the top to the bottom as well as from the outer perimeter to the large central graft cavity of the implant. This optimizes vascularization to the fusion site allowing the implant to be a participant in the fusion process. The implant utilizes machined endplate structures in conjunction with the inherent texture of the porous titanium to provide migration resistance. The implant is offered in individual sterile packages. InTice-C was developed in collaboration with Sites Medical.

 

READ THE REST HERE

 

Globus Medical Announces Appointment of Orthopedic Trauma Division’s Vice President of Sales

AUDUBON, Pa., May 21, 2018 (GLOBE NEWSWIRE) — Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal solutions company, today announced the appointment of Daniel Gregoris to Vice President of Sales for the company’s emerging Orthopedic Trauma division.  Gregoris will be responsible for leading the growth and expansion of Globus Medical’s direct Trauma sales force and the development and execution of all domestic sales strategies within the Trauma business unit.

“Dan shares the company’s values and passion for continuous product innovation and exceptional customer responsiveness,” said Chief Executive Officer Dave Demski.  “His extensive experience in sales management, expertise in the orthopedic trauma space, and proven track record of building dynamic and highly successful sales teams make him an excellent choice to lead our trauma sales force as they enter this new market.”

Prior to joining Globus Medical, Gregoris served as Area Vice President of Sales for DePuy Synthes Trauma, a subsidiary of Johnson and Johnson, and brings over 20 years of combined sales and sales management experience in the orthopedic trauma market.

“I’m so excited to lead the trauma sales efforts for a company with a strong history in quality products and service that truly help surgeons and healthcare systems advance patient care,” Gregoris said. “I am passionate about medical devices and this is where I have spent my entire career. I look forward to leveraging my more than two decades of sales experience and relationships with the Globus commitment to enter and advance orthopedic trauma.”

About Globus Medical, Inc.
Globus Medical, Inc. is a leading musculoskeletal solutions company based in Audubon, PA. The company was founded in 2003 by an experienced team of professionals with a shared vision to create products that enable surgeons to promote healing in patients with musculoskeletal disorders. Additional information can be accessed at http://www.globusmedical.com.

Safe Harbor Statements
All statements included in this press release other than statements of historical fact are forward-looking statements and may be identified by their use of words such as “believe,” “may,” “might,” “could,” “will,” “aim,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “plan” and other similar terms. These forward-looking statements are based on our current assumptions, expectations and estimates of future events and trends. Forward-looking statements are only predictions and are subject to many risks, uncertainties and other factors that may affect our businesses and operations and could cause actual results to differ materially from those predicted. These risks and uncertainties include, but are not limited to, factors affecting our quarterly results, our ability to manage our growth, our ability to sustain our profitability, demand for our products, our ability to compete successfully (including without limitation our ability to convince surgeons to use our products and our ability to attract and retain sales and other personnel), our ability to rapidly develop and introduce new products, our ability to develop and execute on successful business strategies, our ability to comply with changing laws and regulations that are applicable to our businesses, our ability to safeguard our intellectual property, our success in defending legal proceedings brought against us, trends in the medical device industry, general economic conditions, and other risks. For a discussion of these and other risks, uncertainties and other factors that could affect our results, you should refer to the disclosure contained in our most recent annual report on Form 10-K filed with the Securities and Exchange Commission, including the sections labeled “Risk Factors” and “Cautionary Note Concerning Forward-Looking Statements,” and in our Forms 10-Q, Forms 8-K and other filings with the Securities and Exchange Commission. These documents are available at www.sec.gov. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on its business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Given these risks and uncertainties, readers are cautioned not to place undue reliance on any forward-looking statements. Forward-looking statements contained in this press release speak only as of the date of this press release. We undertake no obligation to update any forward-looking statements as a result of new information, events or circumstances or other factors arising or coming to our attention after the date hereof.

Contact:
Brian Kearns
Vice President, Business Development and Investor Relations
Phone: (610) 930-1800
Email:  investors@globusmedical.com
www.globusmedical.com

Zimmer Biomet Announces Call for Applications for the 2018 Connected Health Innovation Award

WARSAW, Ind.May 21, 2018 /PRNewswire/ — Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced a call for applications for its second Connected Health Innovation Award. The Company is accepting applications from individuals, groups and organizations — including academia and industry — from all countries within Europe, the Middle East and Africa (EMEA) region. The award honors digital innovations that help solve unmet needs in the treatment of musculoskeletal and orthopaedic conditions. The winner will receive a €25,000 prize, an opportunity to pilot the technology in one of Zimmer Biomet’s partner hospitals in Europe and to promote the product in Zimmer Biomet’s Connected Health Innovation Lounge in Switzerland for one year.

“The Connected Health Innovation Award has been created to accelerate innovation in the digital health space focused on improving patient outcomes and efficiency in musculoskeletal healthcare,” said Marc Vogels, Zimmer Biomet’s Vice President of Marketing for EMEA Reconstructive and Zimmer Biomet Signature Solutions. “We are excited to acknowledge talented entrepreneurs and provide start-ups the opportunity to impact the way we are going to provide patient care in the future.”

Application Process
Applications for the second Zimmer Biomet Connected Health Innovation Award must be submitted online at www.connectedhealthaward.com/apply by June 15, 2018. Applicants must have a market-ready product, have obtained any necessary regulatory approvals, have first users willing to act as a reference and be able to demonstrate the value and core functionality of the product beyond concepts, papers, sketches, mockups, designs, formula and patents.

Applications will be reviewed by a jury composed of chief executive officers from Europe’s leading orthopaedic and musculoskeletal healthcare facilities. The jury will select five finalists. Finalists will be announced by June 30, 2018, and invited to the Zimmer Biomet EMEA headquarters in Switzerland to present their innovations and compete for the Award on July 10, 2018. Applications and additional information are available at http://www.connectedhealthaward.com.

About Zimmer Biomet
Founded in 1927 and headquartered in Warsaw, Indiana, Zimmer Biomet is a global leader in musculoskeletal healthcare. We design, manufacture and market orthopaedic reconstructive products; sports medicine, biologics, extremities and trauma products; office based technologies; spine, craniomaxillofacial and thoracic products; dental implants; and related surgical products.

We collaborate with healthcare professionals around the globe to advance the pace of innovation. Our products and solutions help treat patients suffering from disorders of, or injuries to, bones, joints or supporting soft tissues. Together with healthcare professionals, we help millions of people live better lives.

We have operations in more than 25 countries around the world and sell products in more than 100 countries. For more information, visit www.zimmerbiomet.com or follow Zimmer Biomet on Twitter at www.twitter.com/zimmerbiomet.

Cautionary Statement Regarding Forward-Looking Statements
This release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Forward-looking statements include, but are not limited to, statements concerning Zimmer Biomet’s expectations, plans, prospects, and product and service offerings, including new product launches and potential clinical successes.  Such statements are based upon the current beliefs and expectations of management and are subject to significant risks, uncertainties and changes in circumstances that could cause actual outcomes and results to differ materially.  For a list and description of some of such risks and uncertainties, see Zimmer Biomet’s periodic reports filed with the U.S. Securities and Exchange Commission (SEC).  These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in Zimmer Biomet’s filings with the SEC.  Forward-looking statements speak only as of the date they are made, and Zimmer Biomet disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.  Readers of this release are cautioned not to rely on these forward-looking statements, since there can be no assurance that these forward-looking statements will prove to be accurate.  This cautionary statement is applicable to all forward-looking statements contained in this release.

ZBH-Corp

SOURCE Zimmer Biomet Holdings, Inc.

Related Links

http://www.zimmer.com